VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin
Executive Summary
Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.
You may also be interested in...
Versartis Links With Teijin In First Licensing Deal
Versartis has signed the first licensing deal for its long-acting growth hormone product, tapping Teijin as a commercial partner in Japan.
FDA lifts hold on Versartis' growth hormone; shares rocket
Shares of Versartis rocketed 33.2% on 6 July after the FDA lifted the partial clinical hold on the firm's investigational new drug application for its long-acting form of recombinant human growth hormone (rhGH) VRS-317, which is being investigated to treat growth hormone deficiency (GHD).
AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.